Caplin Point Laboratories Ltd's Q3FY25 Quarter Results
- 08 Feb 2025
Result Summary
- Caplin Point Laboratories Ltd reported a 4.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.8%.
- Its expenses for the quarter were up by 3.5% QoQ and 12.9% YoY.
- The net profit increased 7.1% QoQ and increased 16.9% YoY.
- The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 18.2 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 524.32 | 503.87 | 452.68 | 4.1% | 15.8% |
Total Expenses | 347.05 | 335.31 | 307.29 | 3.5% | 12.9% |
Profit Before Tax | 177.27 | 168.56 | 145.39 | 5.2% | 21.9% |
Tax | 37.19 | 37.65 | 25.59 | -1.2% | 45.3% |
Profit After Tax | 140.07 | 130.81 | 119.82 | 7.1% | 16.9% |
Earnings Per Share | 18.20 | 17.10 | 15.40 | 6.4% | 18.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Caplin Point Laboratories Ltd is a pharmaceutical company based in India. It specializes in the production and marketing of pharmaceutical formulations and over-the-counter products. The company caters to a variety of therapeutic segments and is known for its strength in emerging markets, especially in Latin America and Africa. As an established player in the pharmaceutical industry, Caplin Point Laboratories focuses on a range of healthcare solutions, including injectables and other formulations. While the company's strategy and recent developments are not detailed in the data provided, Caplin Point Laboratories is recognized for its emphasis on cost-effective production and expanding its footprint in underserved markets.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Caplin Point Laboratories Ltd reported a total income of ₹524.32 crores. This marks a notable quarter-over-quarter (QoQ) increase of 4.1% from ₹503.87 crores in the second quarter of fiscal year 2025 (Q2FY25). Comparing this to the same quarter in the previous fiscal year (Q3FY24), where the total income was ₹452.68 crores, there is a significant year-over-year (YoY) growth of 15.8%. These figures indicate a positive trajectory in revenue generation for the company over both the quarter and the year.
Profitability
The company's profitability metrics for Q3FY25 show a profit before tax (PBT) of ₹177.27 crores, which reflects a 5.2% increase QoQ from ₹168.56 crores in Q2FY25. When compared to Q3FY24, where PBT was ₹145.39 crores, there is a substantial YoY growth of 21.9%. The profit after tax (PAT) for Q3FY25 is ₹140.07 crores, a growth of 7.1% QoQ from ₹130.81 crores in Q2FY25, and a 16.9% YoY increase from ₹119.82 crores in Q3FY24. Additionally, the company reported an earnings per share (EPS) of ₹18.20 in Q3FY25, compared to ₹17.10 in the previous quarter, showing a QoQ increase of 6.4%, and a YoY increase of 18.2% from ₹15.40.
Operating Metrics
The total expenses for Caplin Point Laboratories Ltd in Q3FY25 were ₹347.05 crores, representing a 3.5% QoQ increase from ₹335.31 crores in Q2FY25. Compared to Q3FY24, where total expenses were ₹307.29 crores, there is a YoY rise of 12.9%. The tax expense for Q3FY25 was ₹37.19 crores, slightly down by 1.2% from ₹37.65 crores in the previous quarter, but up 45.3% from ₹25.59 crores in Q3FY24. These financial data points provide a snapshot of the company's operating efficiency and cost management over the reporting periods.
